UCB (OTCMKTS:UCBJY) Stock Price Crosses Below 50 Day Moving Average – Should You Sell?

UCB SA (OTCMKTS:UCBJY)’s share price passed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $143.82 and traded as low as $134.94. UCB shares last traded at $134.94, with a volume of 36,592 shares.

Analysts Set New Price Targets

Several equities analysts recently commented on UCBJY shares. Zacks Research upgraded shares of UCB from a “strong sell” rating to a “hold” rating in a research note on Monday, July 6th. Barclays lowered shares of UCB from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 15th. Finally, Jefferies Financial Group upgraded shares of UCB to a “moderate sell” rating in a report on Monday, June 22nd. One analyst has rated the stock with a Strong Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold”.

UCB Trading Down 1.3%

The company has a current ratio of 1.38, a quick ratio of 1.04 and a debt-to-equity ratio of 0.20. The business has a 50-day moving average price of $143.82 and a 200-day moving average price of $147.85.

UCB Company Profile

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.